Zydus Lifesciences Ltd said in a regulatory filing. Template formulary is a continually updated list of medications, products, and technologies backed by current evidence-based medicine and ...

Zydus Lifesciences Limited (Formerly known as ... There is currently no vaccine to prevent or medicine to treat chikungunya virus infection.On 30 September 2016, Cadila Healthcare and Medicines ...

The Centre for Management of Health Services CMHS and the AlumniampExternal Relations Office at the Indian Institute of ...

and an increasing emphasis on personalized medicine. There is a huge opportunity for developing innovative medications and therapies to address unmet market needs. To provide more durable and ...

The Centre for Management of Health Services (CMHS) and the Alumni & External Relations Office at the Indian Institute of Management Ahmedabad (IIMA), in collaboration with the IIMA Healthcare Alumni ...

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic lateral sclerosis (ALS). The designation ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

Zydus Wellness Ltd announced that its subsidiary, Zydus Wellness Products Ltd, has received a GST demand of Rs 56.33 crore with interest and penalties from the tax authority. The demand relates to ...